Artificial secretion peptides for heterologous protein production
Provided herein, in some embodiments, are artificial secretion peptides capable of directing secretion from Lactobacillus for use, for example, in producing heterologous proteins, including therapeutic proteins.
1. An artificial signal peptide comprising an amino acid sequence that has at least 95% sequence identity to an amino acid sequence of any one of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 11, and SEQ ID NO: 7.
2. The artificial signal peptide of claim 1 , wherein the amino acid sequence has at least 98% sequence identity to an amino acid sequence of any one of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 11, and SEQ ID NO: 7.
3. The artificial secretion signal peptide of claim 2 , wherein the amino acid sequence comprises the amino acid sequence of any one of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO: 11, and SEQ ID NO:7.
4. A protein fused to the artificial secretion signal peptide of claim 1 .
5. The protein of claim 4 , wherein the artificial secretion signal peptide is fused to the N-terminus of the protein.
6. The protein of claim 4 , wherein the protein is a therapeutic protein.
7. The protein of claim 6 , wherein the protein is an antibody, optionally wherein the antibody binds specifically to a viral antigen or a microbial antigen.
8. The protein of claim 6 , wherein the therapeutic protein is a cytokine, optionally wherein the cytokine is IL-10.
9. The protein of claim 6 , wherein the therapeutic protein is an endocrine hormone, optionally wherein the endocrine hormone is glucagon-like peptide 1 (GLP1).
10. The protein of claim 6 , wherein the therapeutic protein is an antimicrobial peptide, optionally wherein the antimicrobial peptide is human beta defensin 1 (hB D1).
11. The artificial secretion signal peptide of claim 1 comprising the amino acid sequence of SEQ ID NO:5, wherein the artificial secretion signal peptide is fused to a therapeutic protein.
12. The artificial secretion signal peptide of claim 11 , wherein the therapeutic protein is selected from interleukin-10 (IL-10), glucagon-like peptide 1 (GLP1), and human beta defensin 1 (hBD1).